Novo Nordisk A/S (NYSE:NVO) Stock Position Reduced by Invesco Ltd.

Invesco Ltd. lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 32.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 349,208 shares of the company's stock after selling 171,244 shares during the quarter. Invesco Ltd.'s holdings in Novo Nordisk A/S were worth $30,039,000 at the end of the most recent reporting period.

• Viking Therapeutics Stock Pops But Struggles to Hold Gains

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. GQG Partners LLC raised its holdings in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $404,910,000. Loomis Sayles & Co. L P lifted its holdings in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Novo Nordisk A/S by 59.8% in the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock valued at $368,451,000 after buying an additional 1,602,549 shares in the last quarter. Finally, Sustainable Growth Advisers LP increased its holdings in Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after buying an additional 1,021,498 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $57.99 on Friday. The stock has a 50-day simple moving average of $76.03 and a 200 day simple moving average of $92.13. Novo Nordisk A/S has a twelve month low of $57.28 and a twelve month high of $148.15. The stock has a market capitalization of $260.23 billion, a PE ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

• Which Healthcare Stock Is the Best Buy Right Now?

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were issued a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's payout ratio is presently 49.54%.

Analyst Ratings Changes

• AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

NVO has been the subject of a number of analyst reports. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday. Finally, UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average price target of $135.00.

Check Out Our Latest Analysis on NVO

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

• Five stocks we like better than Novo Nordisk A/S
• How to Know if a Stock Pays Dividends and When They Are Paid Out
• Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
• How to Invest in the Best Canadian Stocks
• Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar
• What is diluted earnings per share (Diluted EPS)?
• Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novo Nordisk A/S Right Now?

Before you consider Novo Nordisk A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.

While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here